PE20070171A1 - GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa - Google Patents
GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR XaInfo
- Publication number
- PE20070171A1 PE20070171A1 PE2006000745A PE2006000745A PE20070171A1 PE 20070171 A1 PE20070171 A1 PE 20070171A1 PE 2006000745 A PE2006000745 A PE 2006000745A PE 2006000745 A PE2006000745 A PE 2006000745A PE 20070171 A1 PE20070171 A1 PE 20070171A1
- Authority
- PE
- Peru
- Prior art keywords
- thiofen
- carbonylamine
- azepin
- benzo
- tetrahydro
- Prior art date
Links
- 230000002785 anti-thrombosis Effects 0.000 title abstract 2
- 108010074860 Factor Xa Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001408 amides Chemical class 0.000 abstract 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 206010011091 Coronary artery thrombosis Diseases 0.000 abstract 1
- 208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000002528 coronary thrombosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical class NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS DE GLICINAMIDA SUSTITUIDAS DE FORMULA (I), DONDE D ES (II) EN DONDE K1 Y K4 SON INDEPENDIENTEMENTE -CH2-, -CHR7a-, -CR7b7c-; K2 Y K3 SON INDEPENDIENTEMENTE -CH2-, -CHR8a-, -CR8b8c- O UN GRUPO -C(O); ENTRE OTROS; X ES O, S, SULFONA, ENTRE OTROS; A1 ES N O CR10; A2 ES N O CR11; A3 ES N O CR12; R3 ES H O ALQUILO(C1-C3); R4 Y R5 SON INDEPENDIENTEMENTE H, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; M ES UN TIOFENO DE FORMULA (III) DONDE R2 ES H, HALOGENO, ENTRE OTROS; R6 ES H, HALOGENO, ALQUILO(C1-C2) O AMINO. SON PREFERIDOS: AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-CICLOPENTAN-3-TERC.-BUTOXI-1-CABOXILICO, AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-CICLOPENTAN-3-HIDROXI-1-CARBOXILICO, AMIDA DE ACIDO 1-[(5-CLORO-TIOFEN-2-IL)-CARBONILAMINO]-N-(3-METIL-5-HIDROXI-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-IL)-TETRAHIDROFURAN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS TIENEN UN AFECTO ANTITROMBOTICO Y UN EFECTO INHIBIDOR DEL FACTOR Xa, Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES TROMBOTICAS VENOSAS Y ARTERIALES, EMBOLIA PULMONAR, TROMBOSIS CORONARIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05014270 | 2005-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070171A1 true PE20070171A1 (es) | 2007-03-08 |
Family
ID=35907001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000745A PE20070171A1 (es) | 2005-06-30 | 2006-06-27 | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20100216769A1 (es) |
| EP (1) | EP1899330B9 (es) |
| JP (1) | JP4768016B2 (es) |
| KR (1) | KR101321722B1 (es) |
| CN (1) | CN101213195B (es) |
| AR (1) | AR054627A1 (es) |
| AT (1) | ATE489381T1 (es) |
| AU (1) | AU2006265216B2 (es) |
| BR (1) | BRPI0612580A8 (es) |
| CA (1) | CA2613059C (es) |
| CY (1) | CY1111627T1 (es) |
| DE (1) | DE502006008392D1 (es) |
| DK (1) | DK1899330T3 (es) |
| EA (1) | EA015188B1 (es) |
| EC (1) | ECSP078058A (es) |
| ES (1) | ES2357029T3 (es) |
| HR (1) | HRP20110044T2 (es) |
| IL (1) | IL188323A (es) |
| MX (1) | MX2007016253A (es) |
| MY (1) | MY145883A (es) |
| NO (1) | NO340670B1 (es) |
| NZ (1) | NZ565440A (es) |
| PE (1) | PE20070171A1 (es) |
| PL (1) | PL1899330T3 (es) |
| PT (1) | PT1899330E (es) |
| RS (1) | RS51572B (es) |
| SG (1) | SG163540A1 (es) |
| SI (1) | SI1899330T1 (es) |
| TW (1) | TWI392495B (es) |
| UA (1) | UA94910C2 (es) |
| WO (1) | WO2007003536A1 (es) |
| ZA (1) | ZA200708525B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459448B2 (en) | 2004-10-04 | 2008-12-02 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| CA2692440A1 (en) * | 2006-07-20 | 2008-01-24 | Cascade Therapeutics Inc. | Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands |
| PE20081834A1 (es) * | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2220079A2 (en) * | 2007-11-15 | 2010-08-25 | Boehringer Ingelheim International GmbH | Substituted amides, manufacturing and use thereof as medicaments |
| JP5562865B2 (ja) | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| AR074487A1 (es) | 2008-12-05 | 2011-01-19 | Millennium Pharm Inc | Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer. |
| EP2398781A1 (en) * | 2009-02-17 | 2011-12-28 | Msd K.K. | 1,4-benzodiazepin-2-on derivatives |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| ES2953393T3 (es) | 2011-09-20 | 2023-11-10 | Icahn School Med Mount Sinai | Vacunas contra el virus de la influenza y sus usos |
| CN108641002A (zh) | 2012-12-18 | 2018-10-12 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| EP3102200B1 (en) * | 2014-02-07 | 2023-04-05 | Exithera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| CN105622511B (zh) * | 2014-11-03 | 2018-01-23 | 北京瑞都医药科技有限公司 | 一种减肥药物及其制备方法 |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| MA53089B1 (fr) | 2018-07-05 | 2022-11-30 | Bayer Ag | Thiophènecarboxamides substitués et analogues comme agents antibactériens |
| CN111196772B (zh) * | 2018-11-16 | 2022-09-30 | 沈阳化工研究院有限公司 | 一种芳酰氨基异丁酰衍生物及其应用 |
| HUE068308T2 (hu) | 2019-12-20 | 2024-12-28 | Bayer Ag | Tieniloxazolonok és analógok |
| JP7502564B2 (ja) | 2020-11-06 | 2024-06-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855715B1 (en) | 1999-06-14 | 2005-02-15 | Eli Lilly And Company | Serine protease inhibitors |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| EA005893B1 (ru) * | 2000-03-21 | 2005-06-30 | Смитклайн Бичам Корпорейшн | Ингибиторы протеаз |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| EP1401453A4 (en) | 2001-05-17 | 2005-04-06 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| US20060223826A1 (en) | 2002-11-19 | 2006-10-05 | Takeda Pharmaceutical Company Limited Intellectual Property Department | Indole derivatives as somatostatin agonists or antagonists |
| JP2004300133A (ja) * | 2002-11-19 | 2004-10-28 | Takeda Chem Ind Ltd | アミン誘導体 |
| DE10254336A1 (de) | 2002-11-21 | 2004-06-03 | Merck Patent Gmbh | Carbonsäureamide |
| US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
| EP1748997A1 (de) | 2004-05-13 | 2007-02-07 | Boehringer Ingelheim International Gmbh | Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| EP1747217A1 (de) * | 2004-05-13 | 2007-01-31 | Boehringer Ingelheim International GmbH | Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| EP1748996A1 (de) * | 2004-05-13 | 2007-02-07 | Boehringer Ingelheim International GmbH | Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel |
| DE102004047840A1 (de) * | 2004-09-29 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20081834A1 (es) | 2006-12-31 | 2009-01-16 | Boehringer Ingelheim Int | Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos |
-
2006
- 2006-06-27 PE PE2006000745A patent/PE20070171A1/es not_active Application Discontinuation
- 2006-06-28 AU AU2006265216A patent/AU2006265216B2/en not_active Ceased
- 2006-06-28 BR BRPI0612580A patent/BRPI0612580A8/pt not_active Application Discontinuation
- 2006-06-28 JP JP2008517518A patent/JP4768016B2/ja not_active Expired - Fee Related
- 2006-06-28 SI SI200630915T patent/SI1899330T1/sl unknown
- 2006-06-28 DK DK06763910.4T patent/DK1899330T3/da active
- 2006-06-28 PT PT06763910T patent/PT1899330E/pt unknown
- 2006-06-28 CN CN2006800242678A patent/CN101213195B/zh not_active Expired - Fee Related
- 2006-06-28 DE DE502006008392T patent/DE502006008392D1/de active Active
- 2006-06-28 MX MX2007016253A patent/MX2007016253A/es active IP Right Grant
- 2006-06-28 HR HR20110044T patent/HRP20110044T2/hr unknown
- 2006-06-28 UA UAA200800769A patent/UA94910C2/ru unknown
- 2006-06-28 WO PCT/EP2006/063611 patent/WO2007003536A1/de not_active Ceased
- 2006-06-28 NZ NZ565440A patent/NZ565440A/en not_active IP Right Cessation
- 2006-06-28 KR KR1020087002478A patent/KR101321722B1/ko not_active Expired - Fee Related
- 2006-06-28 ES ES06763910T patent/ES2357029T3/es active Active
- 2006-06-28 EP EP06763910A patent/EP1899330B9/de active Active
- 2006-06-28 MY MYPI20063092A patent/MY145883A/en unknown
- 2006-06-28 SG SG201004677-9A patent/SG163540A1/en unknown
- 2006-06-28 US US11/993,426 patent/US20100216769A1/en not_active Abandoned
- 2006-06-28 EA EA200702620A patent/EA015188B1/ru not_active IP Right Cessation
- 2006-06-28 CA CA2613059A patent/CA2613059C/en not_active Expired - Fee Related
- 2006-06-28 AT AT06763910T patent/ATE489381T1/de active
- 2006-06-28 RS RS20110015A patent/RS51572B/sr unknown
- 2006-06-28 PL PL06763910T patent/PL1899330T3/pl unknown
- 2006-06-29 TW TW095123603A patent/TWI392495B/zh not_active IP Right Cessation
- 2006-06-30 AR ARP060102825A patent/AR054627A1/es active IP Right Grant
-
2007
- 2007-10-05 ZA ZA200708525A patent/ZA200708525B/xx unknown
- 2007-10-11 NO NO20075186A patent/NO340670B1/no not_active IP Right Cessation
- 2007-12-20 IL IL188323A patent/IL188323A/en not_active IP Right Cessation
- 2007-12-27 EC EC2007008058A patent/ECSP078058A/es unknown
-
2011
- 2011-02-16 CY CY20111100202T patent/CY1111627T1/el unknown
-
2013
- 2013-03-05 US US13/785,176 patent/US9062034B2/en active Active
-
2015
- 2015-05-19 US US14/716,227 patent/US9676781B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070171A1 (es) | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa | |
| PE20090226A1 (es) | PIRROLIDINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa Y SU PREPARACION | |
| PE20080702A1 (es) | PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa | |
| PE20120330A1 (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
| PE20091065A1 (es) | Derivados bis-(sulfonilamino) en terapia 066 | |
| PE20121806A1 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
| CO5580771A2 (es) | Antagonistas ccr5 como agentes terapeuticos | |
| PE20110118A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| EP1594889A4 (en) | NELL PEPTIDE EXPRESSION SYSTEMS AND BONE-MAKING NELL PEPTIDE ACTIVITY | |
| SK116796A3 (en) | Cyclic peptide derivative, method for the preparation thereof, the use, and pharmaceutical composition containing the same | |
| ECSP088738A (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| PE20080708A1 (es) | Compuestos 2-pirrolidincarboxamida sustituidos como inhibidores de la proteasa que activa el canal respiratorio | |
| AR023837A1 (es) | 1-(p-tienilbencil)-imidazoles como agonistas de los receptores de la angiotensina-(1-7), procedimientos para su preparacion, su utilizacion y preparadosfarmaceuticos que los contienen | |
| PE20080077A1 (es) | Derivados de sulfonilfenilo como antagonistas del receptor de il-8 | |
| AR078201A1 (es) | Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos | |
| PE20060999A1 (es) | Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii | |
| PE20060737A1 (es) | 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION | |
| UY27774A1 (es) | Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona | |
| MA30756B1 (fr) | Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1 | |
| PE34297A1 (es) | Ligandos especificos del neuropeptido y1 | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| BRPI0409739A (pt) | composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio | |
| ES2421447T3 (es) | Métodos para proteger frente a apoptosis usando lipopéptidos | |
| PE20212177A1 (es) | Compuestos y composiciones como moduladores de la senalizacion de tlr | |
| PE20070619A1 (es) | TIENO(2,3-b)PIRIDIN-5-CARBONITRILOS COMO INHIBIDORES DE PROTEINAS QUINASA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |